These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9721433)

  • 21. Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients.
    Oellerich M; Armstrong VW; Streit F; Weber L; Tönshoff B
    Clin Biochem; 2004 Jun; 37(6):424-8. PubMed ID: 15183289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
    Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
    Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and metabolism of sirolimus.
    Gallant-Haidner HL; Trepanier DJ; Freitag DG; Yatscoff RW
    Ther Drug Monit; 2000 Feb; 22(1):31-5. PubMed ID: 10688254
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Coadministration of neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: potentiation of immunosuppressive efficacy and improvement of tolerability of staggered versus simultaneous treatment.
    Hausen B; Boeke K; Berry GJ; Segarra I; Benet LZ; Christians U; Morris RE
    Transplantation; 1999 Apr; 67(7):956-62. PubMed ID: 10221478
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Combined rapamycin eye drop in nanometer vector and poly (lactic acid) wafers of cyclosporine A effectively prevents high-risk corneal allograft rejection in rabbits].
    Jiang W; Sun HM; Li XR; Yuan XB; Wang YQ; Zhang SX; Tian EJ; Yuan JQ
    Zhonghua Yan Ke Za Zhi; 2009 Jun; 45(6):550-5. PubMed ID: 19957680
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An in vitro method for predicting in vivo oral bioavailability of novel immunosuppressive drugs.
    Dias VC; Yatscoff RW
    Clin Biochem; 1996 Feb; 29(1):43-9. PubMed ID: 8929823
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sirolimus rescue therapy for refractory rejection in renal transplantation.
    Hong JC; Kahan BD
    Transplantation; 2001 Jun; 71(11):1579-84. PubMed ID: 11435968
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic drug monitoring for immunosuppressants.
    Wong SH
    Clin Chim Acta; 2001 Nov; 313(1-2):241-53. PubMed ID: 11694265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats.
    Crowe A; Bruelisauer A; Duerr L; Guntz P; Lemaire M
    Drug Metab Dispos; 1999 May; 27(5):627-32. PubMed ID: 10220493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sirolimus pharmacokinetics in pediatric renal transplant recipients receiving calcineurin inhibitor co-therapy.
    Schachter AD; Benfield MR; Wyatt RJ; Grimm PC; Fennell RS; Herrin JT; Lirenman DS; McDonald RA; Munoz-Arizpe R; Harmon WE
    Pediatr Transplant; 2006 Dec; 10(8):914-9. PubMed ID: 17096757
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sirolimus, a new, potent immunosuppressive agent.
    Kelly PA; Gruber SA; Behbod F; Kahan BD
    Pharmacotherapy; 1997; 17(6):1148-56. PubMed ID: 9399599
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients.
    Djebli N; Rousseau A; Hoizey G; Rerolle JP; Toupance O; Le Meur Y; Marquet P
    Clin Pharmacokinet; 2006; 45(11):1135-48. PubMed ID: 17048977
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of sirolimus on the metabolism of apoB100- containing lipoproteins in renal transplant patients.
    Hoogeveen RC; Ballantyne CM; Pownall HJ; Opekun AR; Hachey DL; Jaffe JS; Oppermann S; Kahan BD; Morrisett JD
    Transplantation; 2001 Oct; 72(7):1244-50. PubMed ID: 11602850
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exposure-response relationships and drug interactions of sirolimus.
    Zimmerman JJ
    AAPS J; 2004 Oct; 6(4):e28. PubMed ID: 15760093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and pharmacokinetics of ascending single doses of sirolimus (Rapamune, rapamycin) in pediatric patients with stable chronic renal failure undergoing dialysis.
    Tejani A; Alexander S; Ettenger R; Lerner G; Zimmerman J; Kohaut E; Briscoe DM
    Pediatr Transplant; 2004 Apr; 8(2):151-60. PubMed ID: 15049795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmacokinetics.
    Kovarik JM; Noe A; Berthier S; McMahon L; Langholff WK; Marion AS; Hoyer PF; Ettenger R; Rordorf C
    J Clin Pharmacol; 2003 Feb; 43(2):141-7. PubMed ID: 12616666
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients.
    Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
    Clin Pharmacokinet; 2004; 43(11):741-62. PubMed ID: 15301578
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients.
    Le Meur Y; Djebli N; Szelag JC; Hoizey G; Toupance O; Rérolle JP; Marquet P
    Clin Pharmacol Ther; 2006 Jul; 80(1):51-60. PubMed ID: 16815317
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral efficacy of the macrolide immunosuppressant SDZ RAD and of cyclosporine microemulsion in cynomolgus monkey kidney allotransplantation.
    Schuurman HJ; Ringers J; Schuler W; Slingerland W; Jonker M
    Transplantation; 2000 Mar; 69(5):737-42. PubMed ID: 10755519
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.
    Kovarik JM; Kahan BD; Kaplan B; Lorber M; Winkler M; Rouilly M; Gerbeau C; Cambon N; Boger R; Rordorf C;
    Clin Pharmacol Ther; 2001 Jan; 69(1):48-56. PubMed ID: 11180038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.